Publications by authors named "Samuel Boellner"

Claim this Profile
P
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Samuel W Boellner, Jeffrey G Stark, Suma Krishnan, Yuxin Zhang

Clin Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Robert L Findling, Sharon B Wigal, Oscar G Bukstein, Samuel W Boellner, Howard B Abikoff

Clin Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
Timothy E Wilens, Samuel W Boellner, Frank A López, John M Turnbow, Sharon B Wigal

J Am Acad Child Adolesc Psychiatry· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Joseph Biederman, Samuel W Boellner, Ann Childress, Frank A Lopez, Suma Krishnan

Biol Psychiatry· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Samuel W Boellner, Michael Pennick, Kimberly Fiske, Andrew Lyne, Amir Shojaei

Pharmacotherapy· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Samuel W Boellner, Craig Q Earl, Sanjay Arora

Curr Med Res Opin· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder.
Laurence L Greenhill, Joseph Biederman, Samuel W Boellner, Thomas A Rugino, R Bart Sangal

J Am Acad Child Adolesc Psychiatry· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
Joseph Biederman, James M Swanson, Sharon B Wigal, Samuel W Boellner, Craig Q Earl

J Clin Psychiatry· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Thomas J Spencer, Howard B Abikoff, Daniel F Connor, Joseph Biederman, Steven R Pliszka, Samuel Boellner

Clin Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Joseph Biederman, James M Swanson, Sharon B Wigal, Christopher J Kratochvil, Samuel W Boellner

Pediatrics· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Charles Oo, George Hill, Albert Dorr, Baolian Liu, Samuel Boellner

Eur J Clin Pharmacol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.
Joseph Biederman, Frank A Lopez, Samuel W Boellner, Mark C Chandler

Pediatrics· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis